VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”) is developing new cancer treatments based on novel agents. A biopharmaceutical company committed to advancing the. Poster presentations showcasing early results of DNA damage response targeting technology, deep docking artificial intelligence presented at the Society for Neuro-Oncology (SNO) 29th Annual Meeting held in Houston, Texas, November 21-24 (AI) Drug Discovery Screening at Education Day.
The poster, titled “Leveraging Artificial Intelligence to Discover Novel PARP1 Selective Inhibitors for Use Against Brain Tumors,” identifies selective inhibitors of PARP-1, a key enzyme involved in DNA repair. It emphasizes rapid virtual virtual screening of billions of compounds. Inhibition of PARP-1 plays an important role in brain tumor progression and is expected to increase the sensitivity of cancer cells to treatment.
This poster provided insight into the chemical properties of compounds that affect absorption, stability, and ability to cross the blood-brain barrier. The poster showed comparable or improved PARP-1 selectivity and central nervous system (CNS) exposure compared to AZD9574, a novel development-stage blood-brain barrier penetrant and selective inhibitor of PARP-1. We also introduced candidates that are predicted to be
said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. “Our team achieved an important milestone this fall with initial results from our deep-docking AI screening efforts, which will allow us to evaluate billions of molecular structures within the timeline we outlined at the beginning of our collaboration. “We are excited to present these preliminary findings to leading brain tumor researchers, clinicians, and potential pharmaceutical partners at the prestigious SNO conference.” AI accelerates discovery of best-in-class drug candidates emphasized the transformative power of
“Our innovative approach not only improves the efficiency of drug discovery, but also increases the specificity and efficacy of potential therapeutics. Our new class of PARP-1 selective inhibitors , can offer hope for more effective treatments in the fight against primary brain tumors.” “The next step will be wet-lab validation of target selectivity, metabolic and pharmacokinetic parameters, CNS penetration, and activity. “Selecting lead candidate molecules based on this,” he added. against cancer. ”
First-generation poly(ADP-ribose) polymerase (PARP) inhibitors have dramatically improved patient outcomes in certain mutated cancers, but their inability to cross the blood-brain barrier makes them a poor choice in the treatment of brain malignancies. It has limited usefulness. There are also potentially harmful side effects caused by secondary inhibition of PARP-2. Successful development of PARP-1 selective CNS penetration inhibitors could reduce toxicity while providing new treatment options for brain tumors.
Upcoming video conference calls
Rakovina Therapeutics will host a video conference call on Wednesday, November 27, 2024 at 10 a.m. PST to further discuss data presented at the Society for Neuro-Oncology Annual Meeting and to discuss PARP inhibitors and other developments. Discuss next steps and upcoming milestones for the program.
Register for the webinar or access the live stream: https://us06web.zoom.us/webinar/register/WN_AN3vaQBaSp6p4aRKo05utw#/registration
About the Society of Neuro-Oncology (SNO) Annual Meeting
The SNO Annual Meeting is a major global event in neuro-oncology, bringing together more than 2,600 researchers, clinicians, and scientists from more than 40 countries to advance the field of neuro-oncology. This influential conference brings together leading experts in oncology and provides a platform for the latest research, treatments and innovations. The 2024 conference was held from November 21-24 at the George R. Brown Convention Center in Houston, Texas. For more information, see https://soc-neuro-onc.org/SNOAnnualMeeting/Default.aspx.
About Lacovina Therapeutics
Rakovina Therapeutics is a biopharmaceutical research company focused on developing innovative cancer treatments. Our research is based on a proprietary technology that uses our proprietary Deep-Docking™ platform to target DNA damage responses through artificial intelligence (AI). Using AI, drug candidates can be considered and optimized at a much faster pace than previously possible.
In collaboration with our pharmaceutical partners, we have established a pipeline of distinctive DNA damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials.
For more information, please visit www.rakovinatherapeutics.com.
The TSXV has neither approved nor disapproved the contents of this press release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Notice Regarding Forward-Looking Statements from Rakovina Therapeutics:
This release contains forward-looking statements regarding the Company and their respective businesses, which may include, but are not limited to, statements regarding the Company’s proposed business plans and other statements. Not limited. Forward-looking statements often, but not always, are Variants of such words or phrases (including negative variations), or statements that a particular action, event, or result is likely, are likely, “Yes,” and “Possible.” “may” or “would” be taken, happened, or accomplished. Such statements are based on the current expectations of the Company’s management. The forward-looking events and circumstances described in this release may not occur by certain specified dates or at all, including risks related to the medical device industry, economic factors, etc. that affect us; may differ materially as a result of known and unknown risk factors and uncertainties. , regulatory factors, the stock market in general, risks related to growth and competition.
Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, or there may be other factors that cause results to differ from expectations. Estimated or intended. Forward-looking statements cannot be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the Company cannot predict whether or not they may be the result of new information or future events. Regardless, we undertake no obligation to publicly update or revise any forward-looking statements. , or otherwise. Readers are referred to our most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential impact. A copy can be accessed from our profile page at www.sedarplus.ca.
For more information, please contact us at:
Jeffrey Basha, BA, MBA
Chairman of the Board and Director
(email protected)
Investor information and media:
Susan Shu
Investor information
(email protected)
778-323-0959
